ASH 2022 | Retrospective analysis on the role of allogeneic transplantation in 3L B-NHL in the CAR-T era
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain discusses the results of a retrospective analysis that evaluated the role of allogeneic stem cell transplantation (alloSCT) for the third-line treatment of diffuse large B-cell lymphoma (DLBCL) in the CAR-T therapy era. The study reported similar long-term survival outcomes in both groups despite the fact that patients in the CAR-T group had poorer prognostic features. Whilst CAR-T is the preferred third-line option for DLBCL, alloSCT remains a suitable option for a select subset of patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.
